The oncogene eIF4E: Using biochemical insights to target cancer

Journal of Interferon and Cytokine Research

Volumn 33, Issue 5, 2013, Pages 227-238

  Carroll, Martin ^a   Borden, Katherine L B ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CAP BINDING PROTEIN; CYTARABINE; INITIATION FACTOR 4E; LY 2275796; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; RAS PROTEIN; RIBAVIRIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ANTISENSE THERAPY; BINDING SITE; BIOLOGICAL ACTIVITY; CANCER SURVIVAL; CELL PROLIFERATION; CELLULAR DISTRIBUTION; GENE EXPRESSION; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; MOLECULAR RECOGNITION; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); NONHUMAN; ONCOGENE; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; REVIEW; RING FINGER MOTIF; RNA STABILITY; RNA TRANSLATION; TRANSLATION REGULATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; EUKARYOTIC INITIATION FACTOR-4E; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; ONCOGENES; SIGNAL TRANSDUCTION;

EID: 84877843724     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2012.0142     Document Type: Review

References (136)

1. Altman JK, Glaser H, Sassano A, Joshi S, Ueda T, Watanabe-Fukunaga R, Fukunaga R, Tallman MS, Platanias LC. 2010. Negative regulatory effects of Mnk kinases in the generation of chemotherapy-induced antileukemic responses. Mol Pharmacol 78(4):778-784.
2. Altmann M, Muller PP, Pelletier J, Sonenberg N, Trachsel H. 1989. A mammalian translation initiation factor can substitute for its yeast homologue in vivo. J Biol Chem 264(21):12145-12147.
3. Armengol G, Rojo F, Castellvi J, Iglesias C, Cuatrecasas M, Pons B, Baselga J, Ramon y Cajal S. 2007. 4E-binding protein 1: A key molecular ''funnel factor'' in human cancer with clinical implications. Cancer Res 67(16):7551-7555.
4. Assouline S, Culjkovic B, Cocolakis E, Rousseau C, Beslu N, Amri A, Caplan S, Leber B, Roy DC, Miller WH, Jr., Borden KL. 2009. Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): A proof-of-principle clinical trial with ribavirin. Blood 114(2):257-260.
5. Assouline S, Kraljacic-Culjkovic B, Cocolakis E, Amri A, Bergeron J, Jamal R, Miller WH, Jr., Borden KL. 2011. A Phase I Combination Study of Ribavirin and Low Dose Cytarabine Arabinoside (ara-C) in M4/M5 Acute Myeloid Leukemia (AML) and AML with High eIF4E. Blood (ASH Annual Meeting Abstracts) 118:3606.
6. Avdulov S, Li S, Michalek V, Burrichter D, Peterson M, Perlman DM, Manivel JC, Sonenberg N, Yee D, Bitterman PB, Polunovsky VA. 2004. Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell 5(6):553-563.
7. Berkel HJ, Turbat-Herrera EA, Shi R, de Benedetti A. 2001. Expression of the translation initiation factor eIF4E in the polypcancer sequence in the colon. Cancer Epidemiol Biomarkers Prev 10(6):663-666.
8. Blackshear PJ, Stumpo DJ, Carballo E, Lawrence JC, Jr. 1997. Disruption of the gene encoding the mitogen-regulated translational modulator PHAS-I in mice. J Biol Chem 272(50): 31510-31514.
9. Blagden SP, Willis AE. 2011. The biological and therapeutic relevance of mRNA translation in cancer. Nat Rev Clin Oncol 8(5):280-291.
10. Borden KL, Culjkovic-Kraljacic B. 2010. Ribavirin as an anticancer therapy: Acute myeloid leukemia and beyond? Leuk Lymphoma 51(10):1805-1815.
11. Brown CJ, Verma CS, Walkinshaw MD, Lane DP. 2009. Crystallization of eIF4E complexed with eIF4GI peptide and glycerol reveals distinct structural differences around the capbinding site. Cell Cycle 8(12):1905-1911.
12. Brunet I, Weinl C, Piper M, Trembleau A, Volovitch M, Harris W, Prochiantz A, Holt C. 2005. The transcription factor Engrailed-2 guides retinal axons. Nature 438(7064):94-98.
13. Brunn GJ, Hudson CC, Sekulic A, Williams JM, Hosoi H, Houghton PJ, Lawrence JC, Jr., Abraham RT. 1997. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 277(5322):99-101.
14. Brunn GJ, Williams J, Sabers C, Wiederrecht G, Lawrence JC, Jr., Abraham RT. 1996. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J 15(19):5256-5267.
15. Bush A, Mateyak M, Dugan K, Obaya A, Adachi S, Sedivy J, Cole M. 1998. c-myc null cells misregulate cad and gadd45 but not other proposed c-Myc targets. Genes Dev 12(24):3797-3802.
16. Carberry SE, Darzynkiewicz E, Goss DJ. 1991. A comparison of the binding of methylated cap analogues to wheat germ protein synthesis initiation factors 4F and (iso)4F. Biochemistry 30(6):1624-1627.
17. Carberry SE, Darzynkiewicz E, Stepinski J, Tahara SM, Rhoads RE, Goss DJ. 1990. A spectroscopic study of the binding of N-7-substituted cap analogues to human protein synthesis initiation factor 4E. Biochemistry 29(13):3337-3341.
18. Cargnello M, Tcherkezian J, Dorn JF, Huttlin EL, Maddox PS, Gygi SP, Roux PP. 2012. Phosphorylation of the eukaryotic translation initiation factor 4E-transporter (4E-T) by c-Jun Nterminal kinase promotes stress-dependent P-body assembly. Mol Cell Biol 32(22):4572-4584.
19. Chakraborty P, Wang Y, Wei JH, van Deursen J, Yu H, Malureanu L, Dasso M, Forbes DJ, Levy DE, Seemann J, Fontoura BM. 2008. Nucleoporin levels regulate cell cycle progression and phase-specific gene expression. Dev Cell 15(5):657-667.
20. Chen L, Aktas BH, Wang Y, He X, Sahoo R, Zhang N, Denoyelle S, Kabha E, Yang H, Freedman RY, Supko JG, Chorev M, Wagner G, Halperin JA. 2012. Tumor suppression by small molecule inhibitors of translation initiation. Oncotarget 3(8): 869-881.
21. Cohen N, Sharma M, Kentsis A, Perez JM, Strudwick S, Borden KL. 2001. PML RING suppresses oncogenic transformation by reducing the affinity of eIF4E for mRNA. Embo J 20(16):4547-4559.
22. Crew JP, Fuggle S, Bicknell R, Cranston DW, de Benedetti A, Harris AL. 2000. Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression. Br J Cancer 82(1):161-166.
23. Crew JP, O'Brien TS, Harris AL. 1996. Bladder cancer angiogenesis, its role in recurrence, stage progression and as a therapeutic target. Cancer Metastasis Rev 15(2):221-230.
24. Cridge AG, Castelli LM, Smirnova JB, Selley JN, Rowe W, Hubbard SJ, McCarthy JE, Ashe MP, Grant CM, Pavitt GD. 2010. Identifying eIF4E-binding protein translationallycontrolled transcripts reveals links to mRNAs bound by specific PUF proteins. Nucleic Acids Res 38(22):8039-8050.
25. Culjkovic B, Borden KL. 2009. Understanding and targeting the eukaryotic translation initiation factor eIF4E in head and neck cancer. J Oncol 2009:981679.
26. Culjkovic B, Tan K, Orolicki S, Amri A, Meloche S, Borden KL. 2008. The eIF4E RNA regulon promotes the Akt signaling pathway. J Cell Biol 181(1):51-63.
27. Culjkovic B, Topisirovic I, Borden KL. 2007. Controlling gene expression through RNA regulons: The role of the eukaryotic translation initiation factor eIF4E. Cell Cycle 6(1):65-69.
28. Culjkovic B, Topisirovic I, Skrabanek L, Ruiz-Gutierrez M, Borden KL. 2005. eIF4E promotes nuclear export of cyclin D1 mRNAs via an element in the 3¢UTR. J Cell Biol 169(2): 245-256.
29. Culjkovic B, Topisirovic I, Skrabanek L, Ruiz-Gutierrez M, Borden KL. 2006. eIF4E is a central node of an RNA regulon that governs cellular proliferation. J Cell Biol 175(3):415-426.
30. Culjkovic-Kraljacic B, Baguet A, Volpon L, Amri A, Borden KLB. 2012. The oncogene eIF4E reprograms the nuclear pore complext to promote mRNA export and oncogenic transformation. Cell Rep 2(2):207-215.
31. De Benedetti A, Harris AL. 1999. eIF4E expression in tumors: Its possible role in progression and malignacies. Int J Biochem Cell Biol 31:59-72.
32. De Benedetti A, Joshi-Barve S, Rinker-Schaeffer C, Rhoads RE. 1991. Expression of antisense RNA against initiation factor eIF-4E mRNA in HeLa cells results in lengthened cell division times, diminished translation rates, and reduced levels of both eIF-4E and the p220 component of eIF-4F. Mol Cell Biol 11(11):5435-5445.
33. De Benedetti A, Rhoads RE. 1990. Overexpression of eukaryotic protein synthesis initiation factor 4E in HeLa cells results in aberrant growth and morphology. Proc Natl Acad Sci U S A 87(21):8212-8216.
34. Descamps G, Gomez-Bougie P, Tamburini J, Green A, Bouscary D, Maiga S, Moreau P, Le Gouill S, Pellat-Deceunynck C, Amiot M. 2012. The cap-translation inhibitor 4EGI-1 induces apoptosis in multiple myeloma through Noxa induction. Br J Cancer 106(10):1660-1667.
35. Dostie J, Lejbkowicz F, Sonenberg N. 2000. Nuclear eukaryotic initiation factor 4E (eIF4E) colocalizes with splicing factors in speckles. J Cell Biol 148(2):239-247.
36. Ferraiuolo MA, Basak S, Dostie J, Murray EL, Schoenberg DR, Sonenberg N. 2005. A role for the eIF4E-binding protein 4E-T in P-body formation and mRNA decay. J Cell Biol 170(6): 913-924.
37. Filipowicz W, Furuichi Y, Sierra JM, Muthukrishnan S, Shatkin AJ, Ochoa S. 1976. A protein binding the methylated 5¢-terminal sequence, m7GpppN, of eukaryotic messenger RNA. Proc Natl Acad Sci U S A 73(5):1559-1563.
38. Garre E, Romero-Santacreu L, De Clercq N, Blasco-Angulo N, Sunnerhagen P, Alepuz P. 2011. Yeast mRNA cap-binding protein Cbc1/Sto1 is necessary for the rapid reprogramming of translation after hyperosmotic shock. Mol Biol Cell 23(1): 137-150.
39. German-Retana S, Walter J, Doublet B, Roudet-Tavert G, Nicaise V, Lecampion C, Houvenaghel MC, Robaglia C, Michon T, Le Gall O. 2008. Mutational analysis of plant capbinding protein eIF4E reveals key amino acids involved in biochemical functions and potyvirus infection. J Virol 82(15): 7601-7612.
40. Gingras AC, Kennedy SG, O'Leary MA, Sonenberg N, Hay N. 1998. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev 12(4):502-513.
41. Glue P. 1999. The clinical pharmacology of ribavirin. Semin Liver Dis 19 Suppl 1:17-24.
42. Graff JR, De Benedetti A, Olson JW, Tamez P, Casero RA, Jr., Zimmer SG. 1997. Translation of ODC mRNA and polyamine transport are suppressed in ras-transformed CREF cells by depleting translation initiation factor 4E. Biochem Biophys Res Commun 240(1):15-20.
43. Graff JR, Konicek BW, Vincent TM, Lynch RL, Monteith D, Weir SN, Schwier P, Capen A, Goode RL, Dowless MS, Chen Y, Zhang H, Sissons S, Cox K, McNulty AM, Parsons SH, Wang T, Sams L, Geeganage S, Douglass LE, Neubauer BL, Dean NM, Blanchard K, Shou J, Stancato LF, Carter JH, Marcusson EG. 2007. Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest 117(9):2638-2648.
44. Gu M, Fabrega C, Liu SW, Liu H, Kiledjian M, Lima CD. 2004. Insights into the structure, mechanism, and regulation of scavenger mRNA decapping activity. Mol Cell 14(1):67-80.
45. Haghighat A, Mader S, Pause A, Sonenberg N. 1995. Repression of cap-dependent translation by 4E-binding protein 1: Competition with p220 for binding to eukaryotic initiation factor-4E. EMBO J 14(22):5701-5709.
46. Hong DS, Kurzrock R, Oh Y, Wheler J, Naing A, Brail L, Callies S, Andre V, Kadam SK, Nasir A, Holzer TR, Meric-Bernstam F, Fishman M, Simon G. 2011. A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin Cancer Res 17(20):6582-6591.
47. Hong Z, Cameron CE. 2002. Pleiotropic mechanisms of ribavirin antiviral activities. Prog Drug Res 59:41-69.
48. Hoover DS, Wingett DG, Zhang J, Reeves R, Magnuson NS. 1997. Pim-1 protein expression is regulated by its 5¢-untranslated region and translation initiation factor elF-4E. Cell Growth Differ 8(12):1371-1380.
49. Iborra FJ, Jackson DA, Cook PR. 2001. Coupled transcription and translation within nuclei of mammalian cells. Science 293(5532):1139-1142.
50. Joshi S, Kaur S, Redig AJ, Goldsborough K, David K, Ueda T, Watanabe-Fukunaga R, Baker DP, Fish EN, Fukunaga R, Platanias LC. 2009. Type I interferon (IFN)-dependent activation of Mnk1 and its role in the generation of growth inhibitory responses. Proc Natl Acad Sci U S A 106(29):12097-12102.
51. Joshi S, Sharma B, Kaur S, Majchrzak B, Ueda T, Fukunaga R, Verma AK, Fish EN, Platanias LC. 2011. Essential role for Mnk kinases in type II interferon (IFNgamma) signaling and its suppressive effects on normal hematopoiesis. J Biol Chem 286(8):6017-6026.
52. Kaufman RJ, Murtha-Riel P, Pittman DD, Davies MV. 1993. Characterization of wild-type and Ser53 mutant eukaryotic initiation factor 4E overexpression in mammalian cells. J Biol Chem 268(16):11902-11909.
53. Keene JD. 2007. RNA regulons: Coordination of post-transcriptional events. Nat Rev Genet 8(7):533-543.
54. Keene JD, Lager PJ. 2005. Post-transcriptional operons and regulons co-ordinating gene expression. Chromosome Res 13(3):327-337.
55. Keene JD, Tenenbaum SA. 2002. Eukaryotic mRNPs may represent posttranscriptional operons. Mol Cell 9(6):1161-1167.
56. Kentsis A, Dwyer EC, Perez JM, Sharma M, Chen A, Pan ZQ, Borden KL. 2001. The RING domains of the promyelocytic leukemia protein PML and the arenaviral protein Z repress translation by directly inhibiting translation initiation factor eIF4E. J Mol Biol 312(4):609-623.
57. Kentsis A, Gordon RE, Borden KL. 2002a. Control of biochemical reactions through supramolecular RING domain self-assembly. Proc Natl Acad Sci U S A 99(24):15404-15409.
58. Kentsis A, Gordon RE, Borden KL. 2002b. Self-assembly properties of a model RING domain. Proc Natl Acad Sci U S A 15:15.
59. Kentsis A, Topisirovic I, Culjkovic B, Shao L, Borden KL. 2004. Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap. Proc Natl Acad Sci U S A 101(52):18105-18110.
60. Kentsis A, Volpon L, Topisirovic I, Soll CE, Culjkovic B, Shao L, Borden KL. 2005. Further evidence that ribavirin interacts with eIF4E. RNA 11(12):1762-1766.
61. Khanna-Gupta A, Abayasekara N, Levine M, Sun H, Virgilio M, Nia N, Halene S, Sportoletti P, Jeong JY, Pandolfi PP, Berliner N. 2012. Up-regulation of translation eukaryotic initiation factor 4E in nucleophosmin 1 haploinsufficient cells results in changes in CCAAT enhancer-binding protein alpha activity: Implications in myelodysplastic syndrome and acute myeloid leukemia. J Biol Chem 287(39):32728-32737.
62. Kinkelin K, Veith K, Grunwald M, Bono F. 2012. Crystal structure of a minimal eIF4E-Cup complex reveals a general mechanism of eIF4E regulation in translational repression. RNA 18(9):1624-1634.
63. Knauf U, Tschopp C, Gram H. 2001. Negative regulation of protein translation by mitogen-activated protein kinaseinteracting kinases 1 and 2. Mol Cell Biol 21(16):5500-5511.
64. Ko SY, Guo H, Barengo N, Naora H. 2009. Inhibition of ovarian cancer growth by a tumor-targeting peptide that binds eukaryotic translation initiation factor 4E. Clin Cancer Res 15(13):4336-4347.
65. Konicek BW, Stephens JR, McNulty AM, Robichaud N, Peery RB, Dumstorf CA, Dowless MS, Iversen PW, Parsons S, Ellis KE, McCann DJ, Pelletier J, Furic L, Yingling JM, Stancato LF, Sonenberg N, Graff Jr. 2011. Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases. Cancer Res 71(5):1849-1857.
66. Kraljacic BC, Arguello M, Amri A, Cormack G, Borden K. 2011. Inhibition of eIF4E with ribavirin cooperates with common chemotherapies in primary acute myeloid leukemia specimens. Leukemia 25(7):1197-1200.
67. Lazaris-Karatzas A, Montine KS, Sonenberg N. 1990. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5¢ cap. Nature 345(6275):544-547.
68. Le Bacquer O, Petroulakis E, Paglialunga S, Poulin F, Richard D, Cianflone K, Sonenberg N. 2007. Elevated sensitivity to dietinduced obesity and insulin resistance in mice lacking 4E-BP1 and 4E-BP2. J Clin Invest 117(2):387-396.
69. Lee JW, Choi JJ, Lee KM, Choi CH, Kim TJ, Lee JH, Kim BG, Ahn G, Song SY, Bae DS. 2005. eIF-4E expression is associated with histopathologic grades in cervical neoplasia. Hum Pathol 36(11):1197-1203.
70. Lejbkowicz F, Goyer C, Darveau A, Neron S, Lemieux R, Sonenberg N. 1992. A fraction of the mRNA 5¢ cap-binding protein, eukaryotic initiation factor 4E, localizes to the nucleus. Proc Natl Acad Sci U S A 89(20):9612-9616.
71. Li BD, Gruner JS, Abreo F, Johnson LW, Yu H, Nawas S, McDonald JC, DeBenedetti A. 2002. Prospective study of eukaryotic initiation factor 4E protein elevation and breast cancer outcome. Ann Surg 235(5):732-738; discussion 738-739.
72. Li S, Takasu T, Perlman DM, Peterson MS, Burrichter D, Avdulov S, Bitterman PB, Polunovsky VA. 2003. Translation factor eIF4E rescues cells from Myc-dependent apoptosis by inhibiting cytochrome c release. J Biol Chem 278(5):3015-3022.
73. Liu W, Jankowska-Anyszka M, Piecyk K, Dickson L, Wallace A, Niedzwiecka A, Stepinski J, Stolarski R, Darzynkiewicz E, Kieft J, Zhao R, Jones DN, Davis RE. 2011. Structural basis for nematode eIF4E binding an m(2,2,7)G-Cap and its implications for translation initiation. Nucleic Acids Res 39(20):8820-8832.
74. Lynch M, Chen L, Ravitz MJ, Mehtani S, Korenblat K, Pazin MJ, Schmidt EV. 2005. hnRNP K binds a core polypyrimidine element in the eukaryotic translation initiation factor 4E (eIF4E) promoter, and its regulation of eIF4E contributes to neoplastic transformation. Mol Cell Biol 25(15):6436-6453.
75. Mader S, Lee H, Pause A, Sonenberg N. 1995. The translation initiation factor eIF-4E binds to a common motif shared by the translation factor eIF-4 gamma and the translational repressors 4E-binding proteins. Mol Cell Biol 15(9):4990-4997.
76. Mainwaring LA, Kenney AM. 2011. Divergent functions for eIF4E and S6 kinase by sonic hedgehog mitogenic signaling in the developing cerebellum. Oncogene 30(15):1784-1797.
77. Maquat LE, Tarn WY, Isken O. 2010. The pioneer round of translation: Features and functions. Cell 142(3):368-374.
78. Marcotrigiano J, Gingras AC, Sonenberg N, Burley SK. 1997. Cocrystal structure of the messenger RNA 5¢ cap-binding protein (eIF4E) bound to 7-methyl-GDP. Cell 89(6):951-961.
79. Marcotrigiano J, Gingras AC, Sonenberg N, Burley SK. 1999. Cap-dependent translation initiation in eukaryotes is regulated by a molecular mimic of eIF4G. Mol Cell 3(6):707-716.
80. Martin F, Barends S, Jaeger S, Schaeffer L, Prongidi-Fix L, Eriani G. 2011. Cap-assisted internal initiation of translation of histone H4. Mol Cell 41(2):197-209.
81. Marzec M, Liu X, Wysocka M, Rook AH, Odum N, Wasik MA. 2011. Simultaneous inhibition of mTOR-containing complex 1 (mTORC1) and MNK induces apoptosis of cutaneous T-cell lymphoma (CTCL) cells. PLoS One 6(9):e24849.
82. Matthews-Greer J, Caldito G, de Benedetti A, Herrera GA, Dominguez-Malagon H, Chanona-Vilchis J, Turbat-Herrera EA. 2005. eIF4E as a marker for cervical neoplasia. Appl Immunohistochem Mol Morphol 13(4):367-370.
83. Mazan-Mamczarz K, Lal A, Martindale JL, Kawai T, Gorospe M. 2006. Translational repression by RNA-binding protein TIAR. Mol Cell Biol 26(7):2716-2727.
84. Mendez R, Myers MG, Jr., White MF, Rhoads RE. 1996. Stimulation of protein synthesis, eukaryotic translation initiation factor 4E phosphorylation, and PHAS-I phosphorylation by insulin requires insulin receptor substrate 1 and phosphatidylinositol 3-kinase. Mol Cell Biol 16(6):2857-2864.
85. Michon T, Estevez Y, Walter J, German-Retana S, Le Gall O. 2006. The potyviral virus genome-linked protein VPg forms a ternary complex with the eukaryotic initiation factors eIF4E and eIF4G and reduces eIF4E affinity for a mRNA cap analogue. FEBS J 273(6):1312-1322.
86. Moerke NJ, Aktas H, Chen H, Cantel S, Reibarkh MY, Fahmy A, Gross JD, Degterev A, Yuan J, Chorev M, Halperin JA, Wagner G. 2007. Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell 128(2):257-267.
87. Nathan CA, Carter P, Liu L, Li BD, Abreo F, Tudor A, Zimmer SG, De Benedetti A. 1997a. Elevated expression of eIF4E and FGF-2 isoforms during vascularization of breast carcinomas. Oncogene 15(9):1087-1094.
88. Nathan CA, Liu L, Li BD, Abreo FW, Nandy I, De Benedetti A. 1997b. Detection of the proto-oncogene eIF4E in surgical margins may predict recurrence in head and neck cancer. Oncogene 15(5):579-584.
89. Nedelec S, Foucher I, Brunet I, Bouillot C, Prochiantz A, Trembleau A. 2004. Emx2 homeodomain transcription factor interacts with eukaryotic translation initiation factor 4E (eIF4E) in the axons of olfactory sensory neurons. Proc Natl Acad Sci U S A 101(29):10815-10820.
90. Niessing D, Blanke S, Jackle H. 2002. Bicoid associates with the 5¢-cap-bound complex of caudal mRNA and represses translation. Genes Dev 16(19):2576-2582.
91. Osborne MJ, Volpon L, Kornblatt JA, Culjkovic-Kraljcic B, Baguet A, Borden KLB. 2013. eIF4E3 acts as a tumor suppressor by utilizing an atypical mode of methyl-7 guanosine cap recognition. Proc Natl Acad Sci, in press.
92. Parker R, Sheth U. 2007. P bodies and the control of mRNA translation and degradation. Mol Cell 25(5):635-646.
93. Perl AE, Kasner MT, Shank D, Luger SM, Carroll M. 2012. Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy. Clin Cancer Res 18(6):1716-1725.
94. Pestova TV, Kolupaeva VG, Lomakin IB, Pilipenko EV, Shatsky IN, Agol VI, Hellen CU. 2001. Molecular mechanisms of translation initiation in eukaryotes. Proc Natl Acad Sci U S A 98(13):7029-7036.
95. Pettersson F, Yau C, Dobocan MC, Culjkovic-Kraljacic B, Retrouvay H, Puckett R, Flores LM, Krop IE, Rousseau C, Cocolakis E, Borden KL, Benz CC, Miller WH, Jr. 2011. Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer. Clin Cancer Res 17(9):2874-2884.
96. Polunovsky VA, Rosenwald IB, Tan AT, White J, Chiang L, Sonenberg N, Bitterman PB. 1996. Translational control of programmed cell death: Eukaryotic translation initiation factor 4E blocks apoptosis in growth-factor-restricted fibroblasts with physiologically expressed or deregulated Myc. Mol Cell Biol 16(11):6573-6581.
97. Ptushkina M, von der Haar T, Karim MM, Hughes JM, McCarthy JE. 1999. Repressor binding to a dorsal regulatory site traps human eIF4E in a high cap-affinity state. Embo J 18(14):4068-4075.
98. Ptushkina M, von der Haar T, Vasilescu S, Frank R, Birkenhager R, McCarthy JE. 1998. Cooperative modulation by eIF4G of eIF4E-binding to the mRNA 5¢ cap in yeast involves a site partially shared by p20. Embo J 17(16):4798-4808.
99. Quiocho FA, Hu G, Gershon PD. 2000. Structural basis of mRNA cap recognition by proteins. Curr Opin Struct Biol 10(1):78-86.
100. Rhoads RE. 2009. eIF4E: New family members, new binding partners, new roles. J Biol Chem 284(25):16711-16715.
101. Rinker-Schaeffer CW, Graff JR, De Benedetti A, Zimmer SG, Rhoads RE. 1993. Decreasing the level of translation initiation factor 4E with antisense RNA causes reversal of ras-mediated transformation and tumorigenesis of cloned rat embryo fibroblasts. Int J Cancer 55(5):841-847.
102. Rong L, Livingstone M, Sukarieh R, Petroulakis E, Gingras AC, Crosby K, Smith B, Polakiewicz RD, Pelletier J, Ferraiuolo MA, Sonenberg N. 2008. Control of eIF4E cellular localization by eIF4E-binding proteins, 4E-BPs. RNA 14(7):1318-1327.
103. Roudet-Tavert G, Michon T, Walter J, Delaunay T, Redondo E, Le Gall O. 2007. Central domain of a potyvirus VPg is involved in the interaction with the host translation initiation factor eIF4E and the viral protein HcPro. J Gen Virol 88(Pt 3):1029-1033.
104. Rousseau D, Kaspar R, Rosenwald I, Gehrke L, Sonenberg N. 1996. Translation initiation of ornithine decarboxylase and nucleocytoplasmic transport of cyclin D1 mRNA are increased in cells overexpressing eukaryotic initiation factor 4E. Proc Natl Acad Sci U S A 93(3):1065-1070.
105. Salehi Z, Mashayekhi F. 2006. Expression of the eukaryotic translation initiation factor 4E (eIF4E) and 4E-BP1 in esophageal cancer. Clin Biochem 39(4):404-409.
106. Scheper GC, Proud CG. 2002. Does phosphorylation of the capbinding protein eIF4E play a role in translation initiation? Eur J Biochem 269(22):5350-5359.
107. Schmidt EV. 2004. The role of c-myc in regulation of translation initiation. Oncogene 23(18):3217-3221.
108. Seki N, Takasu T, Mandai K, Nakata M, Saeki H, Heike Y, Takata I, Segawa Y, Hanafusa T, Eguchi K. 2002. Expression of eukaryotic initiation factor 4E in atypical adenomatous hyperplasia and adenocarcinoma of the human peripheral lung. Clin Cancer Res 8(10):3046-3053.
109. Shih JW, Tsai TY, Chao CH, Wu Lee YH. 2008. Candidate tumor suppressor DDX3 RNA helicase specifically represses capdependent translation by acting as an eIF4E inhibitory protein. Oncogene 27(5):700-714.
110. Shih JW, Wang WT, Tsai TY, Kuo CY, Li HK, Wu Lee YH. 2011 Critical roles of RNA helicase DDX3 and its interactions with eIF4E/PABP1 in stress granule assembly and stress response. Biochem J 441(1):119-129.
111. Sonenberg N, Gingras AC. 1998. The mRNA 5¢ cap-binding protein eIF4E and control of cell growth. Curr Opin Cell Biol 10(2):268-275.
112. Sorrells DL, Black DR, Meschonat C, Rhoads R, De Benedetti A, Gao M, Williams BJ, Li BD. 1998. Detection of eIF4E gene amplification in breast cancer by competitive PCR. Ann Surg Oncol 5(3):232-237.
113. Sorrells DL, Ghali GE, Meschonat C, DeFatta RJ, Black D, Liu L, De Benedetti A, Nathan CO, Li BD. 1999. Competitive PCR to detect eIF4E gene amplification in head and neck cancer. Head Neck 21(1):60-65.
114. Tait S, Dutta K, Cowburn D, Warwicker J, Doig AJ, McCarthy JE. 2010. Local control of a disorder-order transition in 4E-BP1 underpins regulation of translation via eIF4E. Proc Natl Acad Sci U S A 107(41):17627-17632.
115. Tamburini J, Green AS, Bardet V, Chapuis N, Park S, Willems L, Uzunov M, Ifrah N, Dreyfus F, Lacombe C, Mayeux P, Bouscary D. 2009. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood 114(8):1618-1627.
116. Tan A, Bitterman P, Sonenberg N, Peterson M, Polunovsky V. 2000. Inhibition of Myc-dependent apoptosis by eukaryotic translation initiation factor 4E requires cyclin D1. Oncogene 19(11):1437-1447.
117. Tan K, Culjkovic B, Amri A, Borden KL. 2008. Ribavirin targets eIF4E dependent Akt survival signaling. Biochem Biophys Res Commun 375(3):341-345.
118. Tan NG, Ardley HC, Scott GB, Rose SA, Markham AF, Robinson PA. 2003. Human homologue of ariadne promotes the ubiquitylation of translation initiation factor 4E homologous protein, 4EHP. FEBS Lett 554(3):501-504.
119. Tao Y, Farsetta DL, Nibert ML, Harrison SC. 2002. RNA synthesis in a cage - structural studies of reovirus polymerase lambda3. Cell 111(5):733-745.
120. Tenenbaum SA, Carson CC, Lager PJ, Keene JD. 2000. Identifying mRNA subsets in messenger ribonucleoprotein complexes by using cDNA arrays. Proc Natl Acad Sci U S A 97(26):14085-14090.
121. Tomoo K, Matsushita Y, Fujisaki H, Abiko F, Shen X, Taniguchi T, Miyagawa H, Kitamura K, Miura K, Ishida T. 2005. Structural basis for mRNA cap-binding regulation of eukaryotic initiation factor 4E by 4E-binding protein, studied by spectroscopic, X-ray crystal structural, and molecular dynamics simulation methods. Biochim Biophys Acta 1753(2):191-208.
122. Topisirovic I, Culjkovic B, Cohen N, Perez JM, Skrabanek L, Borden KL. 2003a. The proline-rich homeodomain protein, PRH, is a tissue-specific inhibitor of eIF4E-dependent cyclin D1 mRNA transport and growth. EMBO J 22(3):689-703.
123. Topisirovic I, Guzman ML, McConnell MJ, Licht JD, Culjkovic B, Neering SJ, Jordan CT, Borden KL. 2003b. Aberrant eukaryotic translation initiation factor 4E-dependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesis. Mol Cell Biol 23(24):8992-9002.
124. Topisirovic I, Kentsis A, Perez JM, Guzman ML, Jordan CT, Borden KL. 2005. Eukaryotic translation initiation factor 4E activity is modulated by HOXA9 at multiple levels. Mol Cell Biol 25(3):1100-1112.
125. Topisirovic I, Ruiz-Gutierrez M, Borden KL. 2004. Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation and mRNA transport activities. Cancer Res 64(23):8639-8642.
126. Topisirovic I, Siddiqui N, Lapointe VL, Trost M, Thibault P, Bangeranye C, Pinol-Roma S, Borden KL. 2009a. Molecular dissection of the eukaryotic initiation factor 4E (eIF4E) exportcompetent RNP. EMBO J 28(8):1087-1098.
127. Topisirovic I, Siddiqui N, Orolicki S, Skrabanek LA, Tremblay M, Hoang T, Borden KL. 2009b. Stability of eukaryotic translation initiation factor 4E mRNA is regulated by HuR, and this activity is dysregulated in cancer. Mol Cell Biol 29(5):1152-1162.
128. Tschopp C, Knauf U, Brauchle M, Zurini M, Ramage P, Glueck D, New L, Han J, Gram H. 2000. Phosphorylation of eIF-4E on Ser 209 in response to mitogenic and inflammatory stimuli is faithfully detected by specific antibodies. Mol Cell Biol Res Commun 3(4):205-211.
129. Tsukiyama-Kohara K, Poulin F, Kohara M, DeMaria CT, Cheng A, Wu Z, Gingras AC, Katsume A, Elchebly M, Spiegelman BM, Harper ME, Tremblay ML, Sonenberg N. 2001. Adipose tissue reduction in mice lacking the translational inhibitor 4EBP1. Nat Med 7(10):1128-1132.
130. Ueda T, Watanabe-Fukunaga R, Fukuyama H, Nagata S, Fukunaga R. 2004. Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development. Mol Cell Biol 24(15):6539-6549.
131. Volpon L, Osborne MJ, Capul AA, de la Torre JC, Borden KL. 2010. Structural characterization of the Z RING-eIF4E complex reveals a distinct mode of control for eIF4E. Proc Natl Acad Sci U S A 107(12):5441-5446.
132. Waskiewicz AJ, Flynn A, Proud CG, Cooper JA. 1997. Mitogenactivated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. EMBO J 16(8):1909-1920.
133. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, Cordon-Cardo C, Pelletier J, Lowe SW. 2004. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428(6980):332-337.
134. Wheater MJ, Johnson PW, Blaydes JP. 2010. The role of MNK proteins and eIF4E phosphorylation in breast cancer cell proliferation and survival. Cancer Biol Ther 10(7):728-735.
135. Zhang M, Fu W, Prabhu S, Moore JC, Ko J, Kim JW, Druker BJ, Trapp V, Fruehauf J, Gram H, Fan HY, Ong ST. 2008. Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance. Mol Cell Biol 28(20):6496-6509.
136. Zhu N, Gu L, Findley HW, Zhou M. 2005. Transcriptional repression of the eukaryotic initiation factor 4E gene by wild type p53. Biochem Biophys Res Commun 335(4):1272-1279.